12.27
-0.64 (-4.96%)
| Previous Close | 12.91 |
| Open | 13.03 |
| Volume | 977,131 |
| Avg. Volume (3M) | 1,152,673 |
| Market Cap | 546,772,032 |
| Price / Sales | 4.90 |
| Price / Book | 2.02 |
| 52 Weeks Range | |
| Earnings Date | 21 Apr 2026 |
| Profit Margin | -101.62% |
| Operating Margin (TTM) | -105.69% |
| Diluted EPS (TTM) | -1.64 |
| Quarterly Revenue Growth (YOY) | 36.40% |
| Total Debt/Equity (MRQ) | 2.22% |
| Current Ratio (MRQ) | 15.88 |
| Operating Cash Flow (TTM) | -56.10 M |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Beta Bionics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.63 |
|
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 6.51% |
| % Held by Institutions | 98.41% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (Truist Securities, 103.75%) | Buy |
| Median | 22.00 (79.30%) | |
| Low | 14.00 (Baird, 14.10%) | Hold |
| Average | 20.33 (65.69%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 13.64 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 18 Feb 2026 | 14.00 (14.10%) | Hold | 13.61 |
| Stifel | 18 Feb 2026 | 22.00 (79.30%) | Buy | 13.61 |
| 04 Feb 2026 | 25.00 (103.75%) | Buy | 14.09 | |
| Truist Securities | 02 Feb 2026 | 25.00 (103.75%) | Buy | 13.70 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |